In one paragraphArticle in bioRxiv : the preprint server for biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from itWhat it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed, 1 citations in OpenAlex.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
5 · Who and what moneyAuthors and funding
15 authors at 6 institutions in 2 countries.
Mehri MonavarianDivision of Molecular Cellular Pathology, Department of Pathology, O'Neal Comprehensive Cancer Center, University of Alabama, Heersink School of Medicine, Birmingham, AL, USA.ORCID 0000-0002-3320-2974 Emily Faith PageDivision of Molecular Cellular Pathology, Department of Pathology, O'Neal Comprehensive Cancer Center, University of Alabama, Heersink School of Medicine, Birmingham, AL, USA.ORCID 0000-0002-1282-116X Resha RajkarnikarDivision of Molecular Cellular Pathology, Department of Pathology, O'Neal Comprehensive Cancer Center, University of Alabama, Heersink School of Medicine, Birmingham, AL, USA.ORCID 0000-0002-8724-0052 Asha KumariDivision of Molecular Cellular Pathology, Department of Pathology, O'Neal Comprehensive Cancer Center, University of Alabama, Heersink School of Medicine, Birmingham, AL, USA.ORCID 0000-0002-2508-9879 Liz Quintero MaciasDivision of Molecular Cellular Pathology, Department of Pathology, O'Neal Comprehensive Cancer Center, University of Alabama, Heersink School of Medicine, Birmingham, AL, USA.ORCID 0000-0001-7641-4582 Felipe MassicanoUAB Biological Data Science Core, The University of Alabama at Birmingham, Birmingham, Alabama, USA.ORCID 0000-0001-9889-9306 Nam Y LeeDivision of Pharmacology, Chemistry and Biochemistry, College of Medicine, University of Arizona, Tucson, AZ, 85721, USA.ORCID 0000-0002-3730-0774 Sarthak SahooDepartment of Bioengineering, Indian Institute of Science, Bangalore, 560012, India.
Nadine HempelDepartment of Medicine, Division of Hematology Oncology, University of Pittsburgh School of Medicine Pittsburgh PA 15213.ORCID 0000-0002-5574-8783 Mohit Kumar JollyDepartment of Bioengineering, Indian Institute of Science, Bangalore, 560012, India.ORCID 0000-0002-6631-2109 Lara IanovUAB Biological Data Science Core, The University of Alabama at Birmingham, Birmingham, Alabama, USA.ORCID 0000-0002-1859-2118 Elizabeth WortheyUAB Biological Data Science Core, The University of Alabama at Birmingham, Birmingham, Alabama, USA.ORCID 0000-0003-4083-7764 Abhyudai SinghDepartment of Electrical and Computer Engineering, University of Delaware, Newark, DE 19716, USA.ORCID 0000-0002-1451-2838 Eugenia V BroudeDepartment of Drug Discovery and Biomedical Sciences, College of Pharmacy, University of South Carolina, Columbia, SC 29208, USA.ORCID 0000-0002-9180-7111 Karthikeyan MythreyeDivision of Molecular Cellular Pathology, Department of Pathology, O'Neal Comprehensive Cancer Center, University of Alabama, Heersink School of Medicine, Birmingham, AL, USA.ORCID 0000-0001-5478-0098 University of Alabama at Birmingham · USIndian Institute of Science Bangalore · INUniversity of South Carolina · USUniversity of Arizona · USUniversity of Delaware · USUniversity of Pittsburgh · US
Funding
XRAY CRYSTALLOGRAPHYP30CA013148 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Robert S Welner · 1985 to 2026
$165.9MVirology CoreP30AI027767 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI OLAF KUTSCH · 1988 to 2026
$84.1MNational Dissemination of I-Corps@NCATS: Accelerating Translation through CommercializationUL1TR003096 · NCATS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI GUTIERREZ, ORLANDO M, KIMBERLY, ROBERT P. · 2019 to 2023
$43.6MWhy is the prevalence of obesity so high in U.S. Southern States? Regional predictors of BMI and obesity treatment response.P30DK056336 · NIDDK · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI James O Hill · 2000 to 2026
$31.9MTargeting NMDA Receptors and Brain Estradiol to Rescue Memory in Aging FemalesP20GM109091 · NIGMS · UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA · PI KIARIS, HIPPOKRATIS, RONINSON, IGOR B · 2014 to 2024
$25.2MPreventing adaptive drug resistance through Mediator kinase inhibitionR01CA266027 · NCI · UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA · PI Hexin Chen, Mengqian Chen · 2022 to 2026
$3.0MRole of Sox2 in Stress Adaptations to Ovarian Cancer Anchorage IndependenceR01CA230628 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI HEMPEL, NADINE, KARTHIKEYAN, MYTHREYE · 2019 to 2023
$2.1MGeneralized fluctuation test for deciphering phenotypic switching within cell populationsR35GM148351 · NIGMS · UNIVERSITY OF DELAWARE · PI Abhyudai Singh · 2023 to 2026
$1.6MPreventing in vivo resistance to PI3K/AKT/mTOR inhibitors through Mediator kinase inhibitionR43CA271996 · NCI · SENEX BIOTECHNOLOGY, INC. · PI BROUDE, EUGENIA V, CHEN, MENGQIAN · 2022 to 2022
$400kLumina III System for UAB Optical ImagingS10OD021697 · OD · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI ZINN, KURT R · 2016 to 2016
$152kNCATS NIH HHS UL1 TR003096NCI NIH HHS P30 CA013148NCI NIH HHS R01 CA230628NCI NIH HHS R01 CA266027NCI NIH HHS R43 CA271996NIAID NIH HHS P30 AI027767NIDDK NIH HHS P30 DK056336NIGMS NIH HHS P20 GM109091NIGMS NIH HHS R35 GM148351NIH HHS S10 OD021697
6 · The paper itselfAbstract
Anoikis resistance or evasion of cell death triggered by cell detachment into suspension is a hallmark of cancer that is concurrent with cell survival and metastasis. The effects of frequent matrix detachment encounters on the development of anoikis resistance in cancer remains poorly defined. Here we show using a panel of ovarian cancer models, that repeated exposure to suspension stress in vitro followed by attached recovery growth leads to the development of anoikis resistance paralleling in vivo development of anoikis resistance in ovarian cancer ascites. This resistance is concurrent with enhanced invasion, chemoresistance and the ability of anoikis adapted cells to metastasize to distant sites. Adapted anoikis resistant cells show a heightened dependency on oxidative phosphorylation and can also evade immune surveillance. We find that such acquired anoikis resistance is not genetic, as acquired resistance persists for a finite duration in the absence of suspension stress. Transcriptional reprogramming is however essential to this process, as acquisition of adaptive anoikis resistance in vitro and in vivo is exquisitely sensitive to inhibition of CDK8/19 Mediator kinase, a pleiotropic regulator of transcriptional reprogramming. Our data demonstrate that growth after recovery from repeated exposure to suspension stress is a direct contributor to metastasis and that inhibition of CDK8/19 Mediator kinase during such adaptation provides a therapeutic opportunity to prevent both local and distant metastasis in cancer.
Identifiers
PMID38106208
PMCPMC10723298
OpenAlexW4389450869
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390